{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:28:47Z","timestamp":1772119727279,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T00:00:00Z","timestamp":1681948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970118"],"award-info":[{"award-number":["81970118"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Youth Medical Talents Project of \u201cKe Jiao Qiang Wei\u201d project of Jiangsu province","award":["QNRC2016449"],"award-info":[{"award-number":["QNRC2016449"]}]},{"name":"Zhenjiang Clinical Research Center of Hematology","award":["SS2018009"],"award-info":[{"award-number":["SS2018009"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s11033-023-08449-7","type":"journal-article","created":{"date-parts":[[2023,4,20]],"date-time":"2023-04-20T10:28:14Z","timestamp":1681986494000},"page":"4955-4963","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The validation and clinical significance of LPCAT1 down-regulation in acute myeloid leukemia"],"prefix":"10.1007","volume":"50","author":[{"given":"Qin","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zijun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaoqun","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Qian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,20]]},"reference":[{"key":"8449_CR1","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1016\/S0140-6736(06)69780-8","volume":"368","author":"E Estey","year":"2006","unstructured":"Estey E, D\u00f6hner H (2006) Acute myeloid leukaemia. Lancet 368:1894\u20131907","journal-title":"Lancet"},{"key":"8449_CR2","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S1470-2045(04)01512-8","volume":"5","author":"F Ferrara","year":"2004","unstructured":"Ferrara F (2004) Unanswered questions in acute myeloid leukaemia. Lancet Oncol 5:443\u2013450","journal-title":"Lancet Oncol"},{"key":"8449_CR3","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/01.moh.0000148760.15412.df","volume":"12","author":"I Avivi","year":"2005","unstructured":"Avivi I, Rowe JM (2005) Prognostic factors in acute myeloid leukemia. Curr Opin Hematol 12:62\u201367","journal-title":"Curr Opin Hematol"},{"key":"8449_CR4","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1053\/beha.2001.0152","volume":"14","author":"D Grimwade","year":"2001","unstructured":"Grimwade D (2001) The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia. Best Pract Res Clin Haematol 14:497\u2013529","journal-title":"Best Pract Res Clin Haematol"},{"key":"8449_CR5","doi-asserted-by":"publisher","first-page":"4325","DOI":"10.1182\/blood-2002-03-0772","volume":"100","author":"JC Byrd","year":"2002","unstructured":"Byrd JC, Mr\u00f3zek K, Dodge RK et al (2002) Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100:4325\u20134336","journal-title":"Blood"},{"key":"8449_CR6","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1182\/blood-2006-06-001149","volume":"109","author":"K Mr\u00f3zek","year":"2007","unstructured":"Mr\u00f3zek K, Marcucci G, Paschka P et al (2007) Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood 109:431\u2013448","journal-title":"Blood"},{"key":"8449_CR7","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1097\/MOH.0b013e32801684c7","volume":"14","author":"K Mr\u00f3zek","year":"2007","unstructured":"Mr\u00f3zek K, D\u00f6hner H, Bloomfield CD (2007) Influence of new molecular prognostic markers in patients with karyotypically normal acute myeloid leukemia: recent advances. Curr Opin Hematol 14:106\u2013114","journal-title":"Curr Opin Hematol"},{"key":"8449_CR8","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1111\/j.1742-4658.2012.08644.x","volume":"279","author":"CR Santos","year":"2012","unstructured":"Santos CR, Schulze A (2012) Lipid metabolism in cancer. FEBS J 279:2610\u20132623","journal-title":"FEBS J"},{"key":"8449_CR9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.bbalip.2004.12.008","volume":"1733","author":"C Kent","year":"2005","unstructured":"Kent C (2005) Regulatory enzymes of phosphatidylcholine biosynthesis: a personal perspective. Biochim Biophys Acta 1733:53\u201366","journal-title":"Biochim Biophys Acta"},{"key":"8449_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1074\/jbc.R800046200","volume":"284","author":"H Shindou","year":"2009","unstructured":"Shindou H, Shimizu T (2009) Acyl-CoA: lysophospholipid acyltransferases. J Biol Chem 284:1\u20135","journal-title":"J Biol Chem"},{"key":"8449_CR11","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.molonc.2013.07.009","volume":"7","author":"K Grupp","year":"2013","unstructured":"Grupp K, Sanader S, Sirma H et al (2013) High lysophosphatidylcholine acyltransferase 1 expression independently predicts high risk for biochemical recurrence in prostate cancers. Mol Oncol 7:1001\u20131011","journal-title":"Mol Oncol"},{"issue":"1","key":"8449_CR12","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1186\/s12935-021-02130-4","volume":"21","author":"RQ He","year":"2021","unstructured":"He RQ, Li JD, Du XF et al (2021) LPCAT1 overexpression promotes the progression of hepatocellular carcinoma. Cancer Cell Int 21(1):442","journal-title":"Cancer Cell Int"},{"key":"8449_CR13","doi-asserted-by":"publisher","first-page":"1584397","DOI":"10.1155\/2022\/1584397","volume":"2022","author":"Q Sun","year":"2022","unstructured":"Sun Q, Liu X, Peng Q et al (2022) ncRNA-mediated high expression of LPCAT1 correlates with poor prognosis and tumor immune infiltration of liver hepatocellular carcinoma. J Immunol Res 2022:1584397","journal-title":"J Immunol Res"},{"key":"8449_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.678714","volume":"11","author":"W Ji","year":"2021","unstructured":"Ji W, Peng Z, Sun B et al (2021) LPCAT1 promotes malignant transformation of hepatocellular carcinoma cells by directly suppressing STAT1. Front Oncol 11:678714","journal-title":"Front Oncol"},{"key":"8449_CR15","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jhep.2013.02.030","volume":"59","author":"Y Morita","year":"2013","unstructured":"Morita Y, Sakaguchi T, Ikegami K et al (2013) Lysophosphatidylcholine acyltransferase 1 altered phospholipid composition and regulated hepatoma progression. J Hepatol 59:292\u2013299","journal-title":"J Hepatol"},{"issue":"3","key":"8449_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2022.100680","volume":"27","author":"L Shen","year":"2022","unstructured":"Shen L, Gu P, Qiu C et al (2022) Lysophosphatidylcholine acyltransferase 1 promotes epithelial-mesenchymal transition of hepatocellular carcinoma via the Wnt\/\u03b2-catenin signaling pathway. Ann Hepatol 27(3):100680","journal-title":"Ann Hepatol"},{"key":"8449_CR17","doi-asserted-by":"publisher","first-page":"7796","DOI":"10.18632\/aging.102287","volume":"11","author":"P Lebok","year":"2019","unstructured":"Lebok P, von Hassel A, Meiners J et al (2019) Up-regulation of lysophosphatidylcholine acyltransferase 1 (LPCAT1) is linked to poor prognosis in breast cancer. Aging (Albany NY) 11:7796\u20137804","journal-title":"Aging (Albany NY)"},{"key":"8449_CR18","doi-asserted-by":"publisher","first-page":"5473","DOI":"10.1007\/s13277-015-3214-8","volume":"36","author":"E Abdelzaher","year":"2015","unstructured":"Abdelzaher E, Mostafa MF (2015) Lysophosphatidylcholine acyltransferase 1 (LPCAT1) upregulation in breast carcinoma contributes to tumor progression and predicts early tumor recurrence. Tumour Biol 36:5473\u20135483","journal-title":"Tumour Biol"},{"issue":"1","key":"8449_CR19","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s12935-021-01965-1","volume":"21","author":"T Zhao","year":"2021","unstructured":"Zhao T, Zhang Y, Ma X et al (2021) Elevated expression of LPCAT1 predicts a poor prognosis and is correlated with the tumour microenvironment in endometrial cancer. Cancer Cell Int 21(1):269","journal-title":"Cancer Cell Int"},{"key":"8449_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120143","volume":"10","author":"T Shida-Sakazume","year":"2015","unstructured":"Shida-Sakazume T, Endo-Sakamoto Y, Unozawa M et al (2015) Lysophosphatidylcholine acyltransferase1 overexpression promotes oral squamous cell carcinoma progression via enhanced biosynthesis of platelet-activating factor. PLoS ONE 10:e0120143","journal-title":"PLoS ONE"},{"issue":"9","key":"8449_CR21","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41419-021-04132-6","volume":"12","author":"M Tao","year":"2021","unstructured":"Tao M, Luo J, Gu T et al (2021) LPCAT1 reprogramming cholesterol metabolism promotes the progression of esophageal squamous cell carcinoma. Cell Death Dis 12(9):845","journal-title":"Cell Death Dis"},{"issue":"2","key":"8449_CR22","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.jid.2021.07.163","volume":"142","author":"Y Huang","year":"2022","unstructured":"Huang Y, Wang Y, Wang Y et al (2022) LPCAT1 promotes cutaneous squamous cell carcinoma via EGFR-mediated protein kinase B\/p38MAPK signaling pathways. J Invest Dermatol 142(2):303-313.e9","journal-title":"J Invest Dermatol"},{"key":"8449_CR23","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13046-019-1092-4","volume":"38","author":"C Wei","year":"2019","unstructured":"Wei C, Dong X, Lu H et al (2019) LPCAT1 promotes brain metastasis of lung adenocarcinoma by up-regulating PI3K\/AKT\/MYC pathway. J Exp Clin Cancer Res 38:95","journal-title":"J Exp Clin Cancer Res"},{"issue":"6","key":"8449_CR24","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.7150\/jca.66126","volume":"13","author":"J Ding","year":"2022","unstructured":"Ding J, Ding X, Leng Z (2022) LPCAT1 promotes gefitinib resistance via upregulation of the EGFR\/PI3K\/AKT signaling pathway in lung adenocarcinoma. J Cancer 13(6):1837\u20131847","journal-title":"J Cancer"},{"key":"8449_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.608932","volume":"11","author":"C Yin","year":"2021","unstructured":"Yin C, Zhang J, Guan W et al (2021) High expression of CLEC11A predicts favorable prognosis in acute myeloid leukemia. Front Oncol 11:608932","journal-title":"Front Oncol"},{"key":"8449_CR26","doi-asserted-by":"publisher","first-page":"D917","DOI":"10.1093\/nar\/gkv1101","volume":"44","author":"FO Bagger","year":"2016","unstructured":"Bagger FO, Sasivarevic D, Sohi SH et al (2016) BloodSpot: a database of gene expression profiles and transcriptional programs for healthy and malignant haematopoiesis. Nucleic Acids Res 44:D917\u2013D924","journal-title":"Nucleic Acids Res"},{"key":"8449_CR27","doi-asserted-by":"publisher","first-page":"620","DOI":"10.7326\/0003-4819-103-4-620","volume":"103","author":"JM Bennett","year":"1985","unstructured":"Bennett JM, Catovsky D, Daniel MT et al (1985) Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 103:620\u2013625","journal-title":"Ann Intern Med"},{"key":"8449_CR28","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","volume":"100","author":"JW Vardiman","year":"2002","unstructured":"Vardiman JW, Harris NL, Brunning RD (2002) The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100:2292\u20132302","journal-title":"Blood"},{"key":"8449_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-0609.1995.tb00225.x","volume":"55","author":"F Lo Coco","year":"1995","unstructured":"Lo Coco F, Foa R (1995) Diagnostic and prognostic advances in the immunophenotypic and genetic characterization of acute leukaemia. Eur J Haematol 55:1\u20139","journal-title":"Eur J Haematol"},{"key":"8449_CR30","doi-asserted-by":"publisher","first-page":"4075","DOI":"10.1182\/blood.V96.13.4075","volume":"96","author":"ML Slovak","year":"2000","unstructured":"Slovak ML, Kopecky KJ, Cassileth PA et al (2000) Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group\/Eastern Cooperative Oncology Group Study. Blood 96:4075\u20134083","journal-title":"Blood"},{"key":"8449_CR31","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s00277-011-1352-7","volume":"91","author":"J Lin","year":"2012","unstructured":"Lin J, Yao DM, Qian J et al (2012) IDH1 and IDH2 mutation analysis in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. Ann Hematol 91:519\u2013525","journal-title":"Ann Hematol"},{"key":"8449_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0026906","volume":"6","author":"J Lin","year":"2011","unstructured":"Lin J, Yao DM, Qian J et al (2011) Recurrent DNMT3A R882 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. PLoS ONE 6:e26906","journal-title":"PLoS ONE"},{"key":"8449_CR33","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.clinbiochem.2012.12.022","volume":"46","author":"X Yang","year":"2013","unstructured":"Yang X, Qian J, Sun A et al (2013) RAS mutation analysis in a large cohort of Chinese patients with acute myeloid leukemia. Clin Biochem 46:579\u2013583","journal-title":"Clin Biochem"},{"key":"8449_CR34","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0045760","volume":"7","author":"J Qian","year":"2012","unstructured":"Qian J, Yao DM, Lin J et al (2012) U2AF1 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome. PLoS ONE 7:e45760","journal-title":"PLoS ONE"},{"key":"8449_CR35","first-page":"6832","volume":"7","author":"XM Wen","year":"2014","unstructured":"Wen XM, Lin J, Yang J et al (2014) Double CEBPA mutations are prognostically favorable in non-M3 acute myeloid leukemia patients with wild-type NPM1 and FLT3-ITD. Int J Clin Exp Pathol 7:6832\u20136840","journal-title":"Int J Clin Exp Pathol"},{"key":"8449_CR36","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3892\/ol.2020.12366","volume":"21","author":"K Wang","year":"2021","unstructured":"Wang K, Wu Z, Si Y et al (2021) Identification of LPCAT1 expression as a potential prognostic biomarker guiding treatment choice in acute myeloid leukemia. Oncol Lett 21:105","journal-title":"Oncol Lett"},{"issue":"4","key":"8449_CR37","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1080\/01478885.2021.1924971","volume":"44","author":"E Abdelzaher Ahmed","year":"2021","unstructured":"Abdelzaher Ahmed E, Abdel Bary Abdel-Latif A, Fahmy AM et al (2021) Differential lysophosphatidylcholine acyltransferase 1 (LPCAT1) expression confers aggressiveness and independently predicts recurrence in bladder urothelial carcinomas. J Histotechnol 44(4):196\u2013205","journal-title":"J Histotechnol"},{"key":"8449_CR38","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.bbacli.2017.03.002","volume":"7","author":"T Pabst","year":"2017","unstructured":"Pabst T, Kortz L, Fiedler GM et al (2017) The plasma lipidome in acute myeloid leukemia at diagnosis in relation to clinical disease features. BBA Clin 7:105\u2013114","journal-title":"BBA Clin"},{"issue":"4","key":"8449_CR39","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S0022-2275(20)39561-4","volume":"8","author":"EL Gottfried","year":"1967","unstructured":"Gottfried EL (1967) Lipids of human leukocytes: relation to celltype. J Lipid Res 8(4):321\u2013327","journal-title":"J Lipid Res"},{"key":"8449_CR40","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1038\/s41419-020-03213-2","volume":"11","author":"JD Zhou","year":"2020","unstructured":"Zhou JD, Zhang TJ, Xu ZJ et al (2020) Genome-wide methylation sequencing identifies progression-related epigenetic drivers in myelodysplastic syndromes. Cell Death Dis 11:997","journal-title":"Cell Death Dis"},{"key":"8449_CR41","doi-asserted-by":"publisher","first-page":"376","DOI":"10.3322\/caac.20085","volume":"60","author":"R Taby","year":"2010","unstructured":"Taby R, Issa JP (2010) Cancer epigenetics. CA Cancer J Clin 60:376\u2013392","journal-title":"CA Cancer J Clin"},{"key":"8449_CR42","doi-asserted-by":"publisher","first-page":"3695","DOI":"10.1111\/cas.13812","volume":"109","author":"K Yamashita","year":"2018","unstructured":"Yamashita K, Hosoda K, Nishizawa N et al (2018) Epigenetic biomarkers of promoter DNA methylation in the new era of cancer treatment. Cancer Sci 109:3695\u20133706","journal-title":"Cancer Sci"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-023-08449-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-023-08449-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-023-08449-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T21:08:45Z","timestamp":1684962525000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-023-08449-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,20]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["8449"],"URL":"https:\/\/doi.org\/10.1007\/s11033-023-08449-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1960977\/v1","asserted-by":"object"}]},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,20]]},"assertion":[{"value":"19 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in compliance with the 1964 Helsinki declaration and was approved by the Ethics Committee of the Affiliated People\u2019s Hospital of Jiangsu University (No. K-20180063-Y).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}